JNK2 inhibits luminal cell commitment in normal mammary glands and tumors
| dc.contributor.advisor | Van Den Berg, Carla | |
| dc.creator | Cantrell, Michael Andrew | en |
| dc.date.accessioned | 2015-08-12T18:49:43Z | en |
| dc.date.issued | 2013-05 | en |
| dc.date.submitted | May 2013 | en |
| dc.date.updated | 2015-08-12T18:49:43Z | en |
| dc.description | text | en |
| dc.description.abstract | Breast cancer is a heterogeneous disease with vastly different tumor progression kinetics and survival outcomes depending upon the differentiation state and gene expression patterns of the tumor. Effective treatments exist for patients with endocrine therapy sensitive or HER2 overexpressing tumors, but targeted treatments are not available for other tumor types. The mechanisms governing mammary tumor phenotype generation could prove critical to finding treatments. The c-Jun N-terminal kinase (JNK) pathway has recently been implicated in the inhibition of breast tumor luminal differentiation (1, 2) and JNK2, in particular, is important in mammary tumorigenesis and tumor progression (3-8). Therefore, the involvement of JNK2 in inhibition of mammary luminal cell differentiation was investigated in normal glands and tumors. Studies found that JNK2 inhibits luminal cell populations in normal mammary ducts. Additionally, JNK2 suppresses Notch activity in stem cell niche of the developing mammary gland. In vitro assays show that control over differentiation by JNK2 is due to suppression of p53-dependent Notch1 expression. Inhibition of luminal cell populations by JNK2 is also apparent in tumor cell models regardless of p53 expression. In the p53-competent Polyoma Middle T-antigen model, Notch1 expression is suppressed by JNK2. In the absence of p53, JNK2 suppresses luminal populations independent of Notch1. In this model, decreased luminal marker expression is accompanied by increased epithelial to mesenchymal transition. It was also found that JNK2-dependent epithelial to mesenchymal transition inhibits luminal populations and is driven by JNK2-dependent suppression of Brca1. JNK2 also confers resistance to estrogen signaling inhibition, and increases the metastatic ability of tumor cells in vivo. These data establish the importance of JNK2 in mammary epithelial cell differentiation in normal glands and tumors. They also suggest that JNK2 may be an effective prognostic marker or treatment target. | en |
| dc.description.department | Cellular and Molecular Biology | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.uri | http://hdl.handle.net/2152/30344 | en |
| dc.subject | Breast cancer | en |
| dc.subject | Notch | en |
| dc.subject | Notch1 | en |
| dc.subject | P53 | en |
| dc.subject | BRCA1 | en |
| dc.subject | JNK | en |
| dc.subject | JNK2 | en |
| dc.subject | Mammary | en |
| dc.subject | EMT | en |
| dc.title | JNK2 inhibits luminal cell commitment in normal mammary glands and tumors | en |
| dc.type | Thesis | en |
| thesis.degree.department | Cellular and Molecular Biology | en |
| thesis.degree.discipline | Cellular and Molecular Biology | en |
| thesis.degree.grantor | The University of Texas at Austin | en |
| thesis.degree.level | Doctoral | en |
| thesis.degree.name | Doctor of Philosophy | en |